{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:59:56Z","timestamp":1780455596643,"version":"3.54.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"NICHD Pediatric Clinical Pharmacology Fellowship","award":["5T32HD069054"],"award-info":[{"award-number":["5T32HD069054"]}]},{"DOI":"10.13039\/100007172","name":"Cincinnati Children\u2019s Hospital Medical Center (CCHMC) Hospital Medicine Fellow Award","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CCHMC Arnold Strauss Fellow Award"},{"name":"Gerber Foundation Novice Research Award"},{"name":"NIGMS R35","award":["1R35 GM146701"],"award-info":[{"award-number":["1R35 GM146701"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We sought to develop population pharmacokinetic (PopPK) models of total and free piperacillin in critically ill children and young adults. We investigated the impact of kidney function and injury biomarkers and the effect of time on pharmacokinetic (PK) parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled patients admitted to a paediatric ICU and prescribed piperacillin\/tazobactam. We collected residual blood from clinical samples for total and free piperacillin concentrations. PopPK models were developed using nonlinear mixed effects modelling. Specific covariates of interest included time after antibiotic initiation, using a 48 h threshold, and urine neutrophil gelatinase-associated lipocalin (uNGAL), a tubular injury biomarker. Monte Carlo simulations investigated target attainment using different dosing regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Total (n\u200a=\u200a695) and free concentrations (n\u200a=\u200a639) from 139 patients were best described by two-compartment models. Creatinine-based estimated glomerular filtration rate (eGFR), uNGAL, and time &amp;gt;48 h after initial dosing were significant covariates of both total and free piperacillin clearance. Regarding central volume, albumin and cumulative fluid balance were significant covariates on total and free piperacillin, respectively. Simulations showed a common regimen of 100 mg\/kg piperacillin\/tazobactam every 6 h over a 30 min infusion is only sufficient for targeting bacteria with MICs of 2 mg\/L or less in patients &amp;gt;30 kg with eGFR &amp;lt;150 mL\/min\/1.73 m2 or &amp;lt;30 kg with eGFR &amp;lt;90 mL\/min\/1.73 m2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Using a large sample of critically ill children, we developed total and free piperacillin population PK models and newly identified uNGAL and time as significant covariates on piperacillin clearance. These models may be used for model-informed precision dosing after external validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf423","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:07:29Z","timestamp":1762348049000},"source":"Crossref","is-referenced-by-count":3,"title":["Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7737-8499","authenticated-orcid":false,"given":"Sonya","family":"Tang Girdwood","sequence":"first","affiliation":[{"name":"Division of Translational and Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]},{"name":"Division of Hospital Medicine, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Rhodes","family":"Hambrick","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Ann and Robert H. Lurie Children\u2019s Hospital of Chicago , Chicago, IL ,","place":["USA"]},{"name":"Department of Pediatrics, Northwestern Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo","family":"Morales Junior","sequence":"additional","affiliation":[{"name":"Division of Translational and Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieko","family":"Punt","sequence":"additional","affiliation":[{"name":"Medimatics , Maastricht ,","place":["The Netherlands"]},{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, OH ,","place":["USA"]},{"name":"Division of Pathology and Laboratory Medicine, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calise","family":"Curry","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lahni","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Stoneman","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigayle","family":"Gibson","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, OH ,","place":["USA"]},{"name":"Division of Critical Care Medicine, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2026011413280834800_dkaf423-B1","author":"Pfizer Inc"},{"key":"2026011413280834800_dkaf423-B2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40262-018-0682-1","article-title":"Piperacillin population pharmacokinetics and dosing regimen optimization in critically ill children with normal and augmented renal clearance","volume":"58","author":"B\u00e9ranger","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2026011413280834800_dkaf423-B3","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/jac\/dkx093","article-title":"Dose optimization of piperacillin\/tazobactam in critically ill children","volume":"72","author":"De Cock","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280834800_dkaf423-B4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00228-012-1413-4","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in neonates and young infants","volume":"69","author":"Li","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"2026011413280834800_dkaf423-B5","doi-asserted-by":"publisher","first-page":"e173219","DOI":"10.1001\/jamapediatrics.2017.3219","article-title":"Association of acute kidney injury with concomitant vancomycin and piperacillin\/tazobactam treatment among hospitalized children","volume":"171","author":"Downes","year":"2017","journal-title":"JAMA Pediatr"},{"key":"2026011413280834800_dkaf423-B6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/ajhp\/zxz125","article-title":"Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients","volume":"76","author":"Buhlinger","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"2026011413280834800_dkaf423-B7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jpids\/piy030","article-title":"Incidence of nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin-tazobactam or cefepime: a cohort study","volume":"8","author":"Cook","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2026011413280834800_dkaf423-B8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jac\/dkac416","article-title":"Relationship between piperacillin concentrations, clinical factors and piperacillin\/tazobactam-associated acute kidney injury","volume":"78","author":"Tang Girdwood","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280834800_dkaf423-B9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/INF.0b013e3182a743c7","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in critically ill young children","volume":"33","author":"Cies","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2026011413280834800_dkaf423-B10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1128\/AAC.02089-15","article-title":"Population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin and tazobactam in critically ill children","volume":"60","author":"Nichols","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413280834800_dkaf423-B11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/jcph.1773","article-title":"Demonstrating feasibility of an opportunistic sampling approach for pharmacokinetic studies of \u03b2-lactam antibiotics in critically ill children","volume":"61","author":"Tang Girdwood","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2026011413280834800_dkaf423-B12","doi-asserted-by":"publisher","first-page":"e0142721","DOI":"10.1128\/AAC.01427-21","article-title":"Population pharmacokinetic modeling of total and free ceftriaxone in critically ill children and young adults and Monte Carlo simulations support twice daily dosing for target attainment","volume":"66","author":"Tang Girdwood","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413280834800_dkaf423-B13","author":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"2026011413280834800_dkaf423-B14","author":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"2026011413280834800_dkaf423-B15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S2352-4642(17)30181-5","article-title":"Assessment of a renal angina index for prediction of severe acute kidney injury in critically ill children: a multicentre, multinational, prospective observational study","volume":"2","author":"Basu","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"2026011413280834800_dkaf423-B16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026011413280834800_dkaf423-B17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","article-title":"Mechanistic basis of using body size and maturation to predict clearance in humans","volume":"24","author":"Anderson","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"2026011413280834800_dkaf423-B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","article-title":"Human renal function maturation: a quantitative description using weight and postmenstrual age","volume":"24","author":"Rhodin","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"2026011413280834800_dkaf423-B19","doi-asserted-by":"publisher","first-page":"107267","DOI":"10.1016\/j.ijantimicag.2024.107267","article-title":"Impact of fluid balance on beta-lactam antibiotics target attainment: insights from a simulation-based meropenem study","volume":"64","author":"Morales","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413280834800_dkaf423-B20","author":"CLSI"},{"key":"2026011413280834800_dkaf423-B21","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/jac\/dkz270","article-title":"Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen","volume":"74","author":"Thorsted","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280834800_dkaf423-B22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/pbc.25287","article-title":"Population pharmacokinetics of the piperacillin component of piperacillin\/tazobactam in pediatric oncology patients with fever and neutropenia","volume":"62","author":"Cies","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2026011413280834800_dkaf423-B23","author":"Hambrick"},{"key":"2026011413280834800_dkaf423-B24","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jacc.2010.11.051","article-title":"The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies","volume":"57","author":"Haase","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026011413280834800_dkaf423-B25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.12.037","article-title":"OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam","volume":"537","author":"Wen","year":"2018","journal-title":"Int J Pharm"},{"key":"2026011413280834800_dkaf423-B26","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.2023.20583","article-title":"Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial","volume":"330","author":"Qian","year":"2023","journal-title":"JAMA"},{"key":"2026011413280834800_dkaf423-B27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrneph.2011.92","article-title":"Implications of augmented renal clearance in critically ill patients","volume":"7","author":"Udy","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2026011413280834800_dkaf423-B28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/antibiotics12030515","article-title":"Hypoalbuminemia and pharmacokinetics: when the misunderstanding of a fundamental concept leads to repeated errors over decades","volume":"12","author":"Gandia","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026011413280834800_dkaf423-B29","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1093\/jac\/dkae274","article-title":"Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation","volume":"79","author":"Morales Junior","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026011413280834800_dkaf423-B30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40262-025-01485-5","article-title":"Population pharmacokinetics of cefepime in critically ill children and young adults: model development and external validation for Monte Carlo simulations and model-informed precision dosing","volume":"64","author":"Morales Junior","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"2026011413280834800_dkaf423-B31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/ki.2013.349","article-title":"Derivation and validation of the renal angina index to improve the prediction of acute kidney injury in critically ill children","volume":"85","author":"Basu","year":"2014","journal-title":"Kidney Int"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf423\/65612880\/dkaf423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf423\/65612880\/dkaf423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:28:13Z","timestamp":1768415293000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf423\/8351039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf423","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,28]]},"article-number":"dkaf423"}}